Royal Bank Of Canada Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by research analysts at Royal Bank Of Canada from $737.00 to $810.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 10.77% from the company’s previous close.

Other equities analysts also recently issued reports about the company. HSBC lifted their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Truist Financial upped their price target on shares of Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a research note on Wednesday. Wells Fargo & Company boosted their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Finally, Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $817.92.

Regeneron Pharmaceuticals Stock Down 1.5%

Regeneron Pharmaceuticals stock traded down $10.89 during midday trading on Thursday, hitting $731.23. 32,070 shares of the company were exchanged, compared to its average volume of 823,642. The company’s fifty day moving average price is $791.29 and its 200-day moving average price is $720.44. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market cap of $75.29 billion, a PE ratio of 18.05, a price-to-earnings-growth ratio of 1.41 and a beta of 0.16. Regeneron Pharmaceuticals has a fifty-two week low of $541.00 and a fifty-two week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $12.81 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals will post 45.37 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares of the company’s stock, valued at approximately $512,550. The trade was a 39.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,946 shares of company stock worth $3,302,458 over the last 90 days. 6.97% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Orbimed Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $11,358,000. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at $5,682,636,000. Contravisory Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $6,327,000. Oxbow Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $3,342,000. Finally, Deutsche Bank AG bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $323,249,000. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.